Your browser is no longer supported. Please, upgrade your browser.
BCEL Atreca, Inc. daily Stock Chart
BCEL [NASD]
Atreca, Inc.
Index- P/E- EPS (ttm)-2.68 Insider Own1.70% Shs Outstand28.02M Perf Week1.84%
Market Cap412.18M Forward P/E- EPS next Y-2.96 Insider Trans-23.67% Shs Float21.86M Perf Month-24.81%
Income-74.30M PEG- EPS next Q-0.76 Inst Own65.50% Short Float10.53% Perf Quarter-16.21%
Sales- P/S- EPS this Y-70.30% Inst Trans0.72% Short Ratio7.54 Perf Half Y-31.87%
Book/sh6.07 P/B2.28 EPS next Y3.60% ROA-36.50% Target Price- Perf Year3.20%
Cash/sh5.08 P/C2.73 EPS next 5Y- ROE-38.10% 52W Range9.51 - 29.35 Perf YTD-10.47%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-52.81% Beta-
Dividend %- Quick Ratio22.50 Sales past 5Y- Gross Margin- 52W Low45.64% ATR1.01
Employees118 Current Ratio22.50 Sales Q/Q- Oper. Margin- RSI (14)41.47 Volatility5.88% 5.80%
OptionableNo Debt/Eq0.00 EPS Q/Q-43.70% Profit Margin- Rel Volume1.10 Prev Close14.11
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume305.20K Price13.85
Recom1.60 SMA20-0.40% SMA50-20.77% SMA200-15.80% Volume331,254 Change-1.84%
Apr-22-20Initiated Wedbush Outperform $27
Apr-22-20Initiated H.C. Wainwright Buy $30
Apr-16-20Initiated Robert W. Baird Outperform $30
Sep-04-19Initiated ROTH Capital Buy $30
Jul-15-19Initiated Stifel Buy $28
Jul-15-19Initiated Evercore ISI Outperform
Jul-15-19Initiated Cowen Outperform
Jul-15-19Initiated Canaccord Genuity Buy $23
Aug-12-20 08:30AM  
Aug-05-20 04:30PM  
Jul-16-20 12:06AM  
Jul-15-20 04:01PM  
12:00PM  
Jul-08-20 08:01AM  
08:01AM  
Jun-22-20 11:46AM  
Jun-15-20 07:31AM  
Jun-11-20 08:00AM  
May-21-20 08:00AM  
May-14-20 04:30PM  
May-13-20 05:00PM  
May-12-20 04:30PM  
Apr-06-20 04:30PM  
Mar-12-20 05:33PM  
Mar-11-20 04:30PM  
Feb-24-20 04:30PM  
Feb-13-20 04:30PM  
Feb-05-20 04:05PM  
Dec-26-19 10:48AM  
Dec-19-19 04:54PM  
Dec-03-19 08:00AM  
Nov-14-19 08:00AM  
Nov-12-19 04:05PM  
Nov-05-19 08:00AM  
Sep-19-19 09:19AM  
Aug-26-19 04:05PM  
Aug-17-19 07:30AM  
Aug-13-19 04:05PM  
Jul-15-19 02:22PM  
Jul-11-19 08:00AM  
Jun-20-19 11:16AM  
Jun-19-19 09:40PM  
08:20AM  
Jun-17-19 10:07AM  
Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in clinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a strategic research collaboration with Merck Sharp & Dohme Corp. to identify the antigenic targets of select antibodies discovered with potential utility in oncology. Atreca, Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Robinson William HewittDirectorJul 13Sale20.235,000101,139408,948Jul 15 09:46 PM
Serafini TitoChief Strategy OfficerJul 13Sale20.2010,000202,018430,220Jul 15 09:45 PM
Greenberg Norman MichaelChief Scientific OfficerJul 01Option Exercise4.5610,27246,84010,272Jul 06 06:02 PM
Greenberg Norman MichaelChief Scientific OfficerJul 01Sale21.8310,272224,2240Jul 06 06:02 PM
Serafini TitoChief Strategy OfficerJun 25Sale25.0160015,008440,220Jun 29 07:39 PM
Robinson William HewittDirectorJun 25Sale25.0260015,010413,948Jun 29 07:38 PM
Serafini TitoChief Strategy OfficerJun 22Sale20.054969,945440,820Jun 23 05:40 PM
Robinson William HewittDirectorJun 22Sale20.05681,363414,548Jun 23 05:42 PM
Robinson William HewittDirectorJun 19Sale20.0310,245205,169414,616Jun 23 05:42 PM
Serafini TitoChief Strategy OfficerJun 19Sale20.034,60492,203441,316Jun 23 05:40 PM
Robinson William HewittDirectorJun 15Sale18.555,00092,728424,861Jun 17 05:35 PM
Serafini TitoChief Strategy OfficerJun 11Sale16.4710,000164,686445,920Jun 12 05:49 PM
Greenberg Norman MichaelChief Scientific OfficerJun 01Option Exercise4.5615,00068,40015,000Jun 03 05:03 PM
Greenberg Norman MichaelChief Scientific OfficerJun 01Sale18.3815,000275,7600Jun 03 05:03 PM
Robinson William HewittDirectorMay 28Sale20.0160012,003429,861May 29 06:50 PM
Serafini TitoChief Strategy OfficerMay 27Sale20.001002,000456,620May 29 06:48 PM
Robinson William HewittDirectorMay 26Sale20.003877,740430,461May 27 05:58 PM
Serafini TitoChief Strategy OfficerMay 26Sale20.002004,000456,720May 27 05:57 PM
Robinson William HewittDirectorMay 18Sale20.001,60032,003430,848May 19 05:41 PM
Serafini TitoChief Strategy OfficerMay 18Sale20.001,70034,004456,920May 19 05:39 PM
Serafini TitoChief Strategy OfficerMay 15Sale20.002,20044,000458,620May 19 05:39 PM
Robinson William HewittDirectorMay 15Sale20.002,10042,000432,448May 19 05:41 PM
Robinson William HewittDirectorMay 13Sale16.825,00084,105434,548May 15 05:45 PM
Serafini TitoChief Strategy OfficerMay 11Sale18.0010,000180,025460,820May 13 07:35 PM
Greenberg Norman MichaelChief Scientific OfficerMay 07Option Exercise4.565,00022,8005,000May 08 05:28 PM
Greenberg Norman MichaelChief Scientific OfficerMay 07Sale18.005,00090,0000May 08 05:28 PM
Greenberg Norman MichaelChief Scientific OfficerMay 01Option Exercise4.5610,00045,60010,000May 04 05:57 PM
Greenberg Norman MichaelChief Scientific OfficerMay 01Sale15.0310,000150,2760May 04 05:57 PM
Serafini TitoChief Strategy OfficerApr 16Sale16.2810,000162,761470,820Apr 20 05:32 PM
Robinson William HewittDirectorApr 16Sale16.255,00081,271439,548Apr 20 05:30 PM
Greenberg Norman MichaelChief Scientific OfficerApr 14Option Exercise4.565,00022,8005,000Apr 16 06:28 PM
Greenberg Norman MichaelChief Scientific OfficerApr 14Sale18.005,00090,0000Apr 16 06:28 PM
Greenberg Norman MichaelChief Scientific OfficerApr 08Option Exercise4.568,00036,4808,000Apr 10 05:17 PM
Greenberg Norman MichaelChief Scientific OfficerApr 08Sale15.018,000120,1010Apr 10 05:17 PM
Greenberg Norman MichaelChief Scientific OfficerApr 01Option Exercise4.562,0009,1202,000Apr 02 06:18 PM
Greenberg Norman MichaelChief Scientific OfficerApr 01Sale15.212,00030,4220Apr 02 06:18 PM
Orwin John APresident & CEOMar 17Buy12.796,00076,7406,000Mar 19 06:52 PM
Greenberg Norman MichaelChief Scientific OfficerMar 02Option Exercise4.5615,00068,40015,000Mar 04 06:18 PM
Greenberg Norman MichaelChief Scientific OfficerMar 02Sale24.0715,000360,9840Mar 04 06:18 PM
Cavet GuyChief Technical OfficerFeb 25Option Exercise4.562,1009,57694,858Feb 26 06:24 PM
Cavet GuyChief Technical OfficerFeb 25Sale20.647,100146,53887,758Feb 26 06:24 PM
Greenberg Norman MichaelChief Scientific OfficerFeb 03Option Exercise4.5615,00068,40015,000Feb 04 06:00 PM
Greenberg Norman MichaelChief Scientific OfficerFeb 03Sale19.6515,000294,7680Feb 04 06:00 PM
Cavet GuyChief Technical OfficerJan 27Sale20.0010,000200,00092,758Jan 29 04:05 PM
Greenberg Norman MichaelChief Scientific OfficerJan 24Option Exercise4.565,00022,8005,000Jan 27 04:10 PM
Greenberg Norman MichaelChief Scientific OfficerJan 24Sale18.475,00092,3460Jan 27 04:10 PM
Greenberg Norman MichaelChief Scientific OfficerJan 17Option Exercise4.5610,00045,60010,000Jan 22 04:15 PM
Cavet GuyChief Technical OfficerJan 17Option Exercise5.161,9199,902109,677Jan 22 04:16 PM
Cavet GuyChief Technical OfficerJan 17Sale14.906,919103,065102,758Jan 22 04:16 PM
Greenberg Norman MichaelChief Scientific OfficerJan 17Sale14.9010,000148,9920Jan 22 04:15 PM